On Tuesday, June 18, 2019, Cardiovascular Systems' CSII Chairman, President and Chief Executive Officer, Scott Ward, will present at the Raymond James Life Sciences & MedTech Conference at 9:45 a.m. Eastern Time.
You may access the live audio webcast, as well as a replay on the company's investor relations website, https://investors.csi360.com/events-and-presentations/events-calendar/default.aspx.
About Cardiovascular Systems, Inc.
Cardiovascular Systems,
Inc., based in St. Paul, Minn., is a medical device company focused on
developing and commercializing innovative solutions for treating
vascular and coronary disease. The company's Orbital Atherectomy Systems
treat calcified and fibrotic plaque in arterial vessels throughout the
leg and heart in a few minutes of treatment time, and address many of
the limitations associated with existing surgical, catheter and
pharmacological treatment alternatives. The U.S. FDA granted 510(k)
clearance for the use of the Diamondback Orbital Atherectomy System in
peripheral arteries in August 2007. In October 2013, the company
received FDA approval for the use of the Diamondback Orbital Atherectomy
System in coronary arteries. The Stealth 360® Peripheral
Orbital Atherectomy System (OAS) received CE Mark in October 2014. In
March 2017, the company received PMDA approval in Japan for the
Diamondback 360® Coronary OAS Micro Crown and
reimbursement approval effective February 2018. Over 450,000 of CSI's
devices have been sold to leading institutions worldwide. For more
information, visit the company's website at www.csi360.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005005/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.